On the origin of relapse in AML

Area of Science:

• Hematology
• Cancer Biology
• Stem Cell Research

Background:

• Acute myeloid leukemia (AML) often relapses despite initial treatment.
• Leukemia stem cells (LSCs) are implicated in AML persistence and relapse.
• Mechanisms driving LSC therapy resistance remain incompletely understood.

Purpose of the Study:

• To investigate the role of preexisting therapy-resistant LSC populations in AML relapse.
• To identify the cellular origins of treatment failure in acute myeloid leukemia.

Main Methods:

• Utilized patient-derived xenograft models of AML.
• Employed single-cell RNA sequencing to profile LSC heterogeneity.
• Conducted functional assays to assess LSC chemoresistance.

Main Results:

• Identified distinct LSC subpopulations with inherent resistance to standard chemotherapy prior to treatment initiation.
• Demonstrated that these preexisting resistant LSCs are responsible for initiating leukemia regrowth upon therapy cessation.
• Showcased the heterogeneity of LSC resistance mechanisms.

Conclusions:

• Therapy-resistant LSCs are not acquired but are preexisting components of the leukemia clone.
• Targeting these specific resistant LSC populations may offer a novel therapeutic strategy to prevent AML relapse.
• Future research should focus on identifying and eliminating these critical LSC reservoirs.